Astellas Pharma Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Equivalents	281,605	188,372	335,687	376,840	315,986
Cash & Short-Term Investments	281,605	188,372	335,687	376,840	315,986
Cash Growth	49.49%	-43.89%	-10.92%	19.26%	-3.11%
Accounts Receivable	746,808	632,525	534,985	427,965	382,462
Other Receivables	14,955	13,691	13,051	17,813	21,539
Receivables	761,763	646,216	548,036	445,778	404,001
Inventory	331,014	297,261	248,738	174,386	153,072
Other Current Assets	47,541	69,500	62,269	52,950	50,295
Total Current Assets	1,421,923	1,201,349	1,194,730	1,049,954	923,354
Property, Plant & Equipment	358,424	328,921	293,742	286,459	269,044
Long-Term Investments	20,297	172,239	163,018	145,028	141,206
Goodwill	441,175	415,207	418,694	328,411	303,030
Other Intangible Assets	996,932	1,123,714	1,453,824	562,496	623,431
Long-Term Deferred Tax Assets	146,588	98,113	45,594	84,169	72,331
Other Long-Term Assets	181,703	1	1	1	-1
Total Assets	3,567,042	3,339,544	3,569,603	2,456,518	2,332,395
Accounts Payable	199,752	187,840	185,193	140,236	130,739
Accrued Expenses	-	169,119	155,233	143,817	136,553
Short-Term Debt	-	184,874	420,393	75,000	90,000
Current Portion of Long-Term Debt	245,952	81,658	51,885	-	50,000
Current Portion of Leases	-	16,335	14,944	13,546	17,730
Current Income Taxes Payable	68,934	34,549	38,515	5,137	32,388
Other Current Liabilities	703,763	387,235	419,562	348,298	230,001
Total Current Liabilities	1,218,401	1,061,610	1,285,725	726,034	687,411
Long-Term Debt	320,000	564,893	449,937	54,217	676
Long-Term Leases	-	89,326	70,756	61,461	55,014
Pension & Post-Retirement Benefits	21,473	22,746	24,674	24,818	37,226
Long-Term Deferred Tax Liabilities	1,275	5,353	51,346	6,048	5,823
Other Long-Term Liabilities	175,009	82,361	91,177	75,986	85,937
Total Liabilities	1,736,158	1,826,289	1,973,615	948,564	872,087
Common Stock	103,001	103,001	103,001	103,001	103,001
Additional Paid-In Capital	185,162	185,259	184,070	181,280	179,467
Retained Earnings	902,836	740,939	809,400	908,158	944,261
Treasury Stock	-34,945	-37,524	-33,783	-25,123	-13,934
Comprehensive Income & Other	672,990	521,580	533,300	340,638	247,513
Total Common Equity	1,829,044	1,513,255	1,595,988	1,507,954	1,460,308
Minority Interest	1,840	-	-	-	-
Shareholders' Equity	1,830,884	1,513,255	1,595,988	1,507,954	1,460,308
Total Liabilities & Equity	3,567,042	3,339,544	3,569,603	2,456,518	2,332,395
Total Debt	565,952	937,086	1,007,915	204,224	213,420
Net Cash (Debt)	-284,347	-748,714	-672,228	172,616	102,566
Net Cash Growth	-	-	-	68.30%	116.09%
Net Cash Per Share	-158.22	-416.61	-373.53	94.58	55.42
Filing Date Shares Outstanding	1,791	1,790	1,793	1,797	1,827
Total Common Shares Outstanding	1,791	1,790	1,793	1,797	1,827
Working Capital	203,522	139,739	-90,995	323,920	235,943
Book Value Per Share	1020.96	845.25	890.07	839.26	799.26
Tangible Book Value	390,937	-25,666	-276,530	617,047	533,847
Tangible Book Value Per Share	218.22	-14.34	-154.22	343.42	292.19

Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.